Skip to main content
Top
Published in: Drugs 1/2017

Open Access 01-01-2017 | Systematic Review

Topiramate in the Treatment of Generalized Convulsive Status Epilepticus in Adults: A Systematic Review with Individual Patient Data Analysis

Authors: Francesco Brigo, Nicola Luigi Bragazzi, Stanley C. Igwe, Raffaele Nardone, Eugen Trinka

Published in: Drugs | Issue 1/2017

Login to get access

Abstract

Background

Generalized convulsive status epilepticus (GCSE) is a medical emergency associated with high morbidity and mortality that requires prompt medical intervention. Topiramate (TPM) is an antiepileptic drug effective against a broad spectrum of seizure types, and has been proposed as a possible therapeutic option for super-refractory status epilepticus (SRSE), the most severe form of GCSE.

Aim

This review aimed to evaluate the role of TPM in GCSE, including SRSE.

Methods

MEDLINE, CENTRAL, ClinicalTrials.gov, LILACS, Google Scholar, and Opengrey.eu were systematically searched. We compared: (1) patients who did and who did not receive TPM as their last drug; (2) patients receiving TPM as the last drug and achieving SE control and patients receiving TPM as the last drug but without termination of SE.

Results

The literature search yielded 1164 results, with individual data available for 35 patients (six with SRSE) from four studies. SE was controlled in 68.6% of patients receiving TPM either as the last drug (20) or not (15), and in 14 of the 20 patients receiving TPM as the last drug (70%). Only six patients received TPM for SRSE; in five of them, TPM was administered as the last drug with resolution of SE in four. When comparing patients who did and did not receive TPM as the last drug, no statistically significant difference was found for any of the variables considered; similarly, no difference was found comparing patients receiving TPM as the last drug and achieving SE control with those receiving TPM as the last drug but without termination of SE.

Conclusions

The lack of a statistically significant difference is likely to be due to the small sample size. In only a few patients was TPM used for SRSE. There is an unmet need for high-quality studies to evaluate the role of TPM in GCSE.
Appendix
Available only for authorised users
Literature
1.
go back to reference Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus: report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56:1515–23.CrossRefPubMed Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus: report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56:1515–23.CrossRefPubMed
2.
go back to reference Ong CT, Wong YS, Sung SF, Wu CS, Hsu YC, Su YH, et al. Underestimated rate of status epilepticus according to the traditional definition of status epilepticus. Sci World J. 2015;2015:801834.CrossRef Ong CT, Wong YS, Sung SF, Wu CS, Hsu YC, Su YH, et al. Underestimated rate of status epilepticus according to the traditional definition of status epilepticus. Sci World J. 2015;2015:801834.CrossRef
3.
go back to reference Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology. 1998;50:735–41.CrossRefPubMed Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology. 1998;50:735–41.CrossRefPubMed
4.
go back to reference Rosenow F, Hamer HM, Knake S. The epidemiology of convulsive and nonconvulsive status epilepticus. Epilepsia. 2007;48(Suppl 8):82–4.CrossRefPubMed Rosenow F, Hamer HM, Knake S. The epidemiology of convulsive and nonconvulsive status epilepticus. Epilepsia. 2007;48(Suppl 8):82–4.CrossRefPubMed
6.
go back to reference Trinka E, Höfler J, Leitinger M, Rohracher A, Kalss G, Brigo F. Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother. 2016;17:513–34.CrossRefPubMed Trinka E, Höfler J, Leitinger M, Rohracher A, Kalss G, Brigo F. Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother. 2016;17:513–34.CrossRefPubMed
7.
go back to reference Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135:2314–28.CrossRefPubMed Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135:2314–28.CrossRefPubMed
8.
go back to reference Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802–18.CrossRefPubMed Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802–18.CrossRefPubMed
9.
go back to reference Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol. 2013;260:421–8.CrossRefPubMed Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol. 2013;260:421–8.CrossRefPubMed
10.
go back to reference Leitinger M, Kalss G, Rohracher A, Pilz G, Novak H, Höfler J, Deak I, Kuchukhidze G, Dobesberger J, Wakonig A, Trinka E. Predicting outcome of status epilepticus. Epilepsy Behav. 2015;49:126–30.CrossRefPubMed Leitinger M, Kalss G, Rohracher A, Pilz G, Novak H, Höfler J, Deak I, Kuchukhidze G, Dobesberger J, Wakonig A, Trinka E. Predicting outcome of status epilepticus. Epilepsy Behav. 2015;49:126–30.CrossRefPubMed
11.
go back to reference Brigo F, Storti M, Del Felice A, Fiaschi A, Bongiovanni LG. IV Valproate in generalized convulsive status epilepticus: a systematic review. Eur J Neurol. 2012;19:1180–91.CrossRefPubMed Brigo F, Storti M, Del Felice A, Fiaschi A, Bongiovanni LG. IV Valproate in generalized convulsive status epilepticus: a systematic review. Eur J Neurol. 2012;19:1180–91.CrossRefPubMed
12.
go back to reference Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2014;9:CD003723. Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2014;9:CD003723.
13.
go back to reference Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl 1):S3–9.CrossRefPubMed Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl 1):S3–9.CrossRefPubMed
14.
go back to reference Kim W, Kwon SY, Cho AH, Lim SC, Kim YI, Shon YM. Effectiveness of topiramate in medically complicated patients with status epilepticus or acute refractory seizures. J Epilepsy Res. 2011;1:52–6.CrossRefPubMedPubMedCentral Kim W, Kwon SY, Cho AH, Lim SC, Kim YI, Shon YM. Effectiveness of topiramate in medically complicated patients with status epilepticus or acute refractory seizures. J Epilepsy Res. 2011;1:52–6.CrossRefPubMedPubMedCentral
15.
go back to reference Hottinger A, Sutter R, Marsch S, Rüegg S. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study. CNS Drugs. 2012;26:761–72.CrossRefPubMed Hottinger A, Sutter R, Marsch S, Rüegg S. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study. CNS Drugs. 2012;26:761–72.CrossRefPubMed
16.
go back to reference Asadi-Pooya AA, Jahromi MJ, Izadi S, Emami Y. Treatment of refractory generalized convulsive status epilepticus with enteral topiramate in resource limited settings. Seizure. 2015;24:114–7.CrossRefPubMed Asadi-Pooya AA, Jahromi MJ, Izadi S, Emami Y. Treatment of refractory generalized convulsive status epilepticus with enteral topiramate in resource limited settings. Seizure. 2015;24:114–7.CrossRefPubMed
17.
go back to reference Stojanova V, Rossetti AO. Oral topiramate as an add-on treatment for refractory status epilepticus. Acta Neurol Scand. 2012;125:e7–11.CrossRefPubMed Stojanova V, Rossetti AO. Oral topiramate as an add-on treatment for refractory status epilepticus. Acta Neurol Scand. 2012;125:e7–11.CrossRefPubMed
18.
go back to reference Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof. 2002;25:76–97.CrossRefPubMed Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof. 2002;25:76–97.CrossRefPubMed
19.
go back to reference Brigo F, Nardone R, Tezzon F, Trinka E. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-analysis. Epilepsy Behav. 2015;49:325–36.CrossRefPubMed Brigo F, Nardone R, Tezzon F, Trinka E. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-analysis. Epilepsy Behav. 2015;49:325–36.CrossRefPubMed
20.
go back to reference Minicucci F, Muscas G, Perucca E, Capovilla G, Vigevano F, Tinuper P. Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy. Epilepsia. 2006;47(Suppl 5):9–15.CrossRefPubMed Minicucci F, Muscas G, Perucca E, Capovilla G, Vigevano F, Tinuper P. Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy. Epilepsia. 2006;47(Suppl 5):9–15.CrossRefPubMed
21.
go back to reference Shorvon S, Baulac M, Cross H, Trinka E, Walker M, TaskForce on Status Epilepticus of the ILAE Commission for European Affairs. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia. 2008;49:1277–85.CrossRefPubMed Shorvon S, Baulac M, Cross H, Trinka E, Walker M, TaskForce on Status Epilepticus of the ILAE Commission for European Affairs. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia. 2008;49:1277–85.CrossRefPubMed
22.
go back to reference Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, Holtkamp M, European Federation of Neurological Societies. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17:348–55.CrossRefPubMed Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, Holtkamp M, European Federation of Neurological Societies. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17:348–55.CrossRefPubMed
23.
go back to reference Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ, Jr., Shutter L, Sperling MR, Treiman DM, Vespa PM, Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3–23. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ, Jr., Shutter L, Sperling MR, Treiman DM, Vespa PM, Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3–23.
24.
go back to reference Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the american epilepsy society. Epilepsy Curr. 2016;16:48–61.CrossRefPubMedPubMedCentral Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the american epilepsy society. Epilepsy Curr. 2016;16:48–61.CrossRefPubMedPubMedCentral
25.
go back to reference Synowiec AS, Yandora KA, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res. 2012;98:232–7.CrossRefPubMed Synowiec AS, Yandora KA, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res. 2012;98:232–7.CrossRefPubMed
26.
go back to reference Madžar D, Kuramatsu JB, Gerner ST, Huttner HB. Assessing the value of topiramate in refractory status epilepticus. Seizure. 2016;38:7–10.CrossRefPubMed Madžar D, Kuramatsu JB, Gerner ST, Huttner HB. Assessing the value of topiramate in refractory status epilepticus. Seizure. 2016;38:7–10.CrossRefPubMed
27.
go back to reference Akyildiz BN, Kumandaş S. Treatment of pediatric refractory status epilepticus with topiramate. Childs Nerv Syst. 2011;27:1425–30.CrossRefPubMed Akyildiz BN, Kumandaş S. Treatment of pediatric refractory status epilepticus with topiramate. Childs Nerv Syst. 2011;27:1425–30.CrossRefPubMed
28.
go back to reference Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ. The use of topiramate in refractory status epilepticus. Neurology. 2003;60:332–4.CrossRefPubMed Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ. The use of topiramate in refractory status epilepticus. Neurology. 2003;60:332–4.CrossRefPubMed
29.
go back to reference Kortland LM, Alfter A, Bähr O, Carl B, Dodel R, Freiman TM, Hubert K, Jahnke K, Knake S, von Podewils F, Reese JP, Runge U, Senft C, Steinmetz H, Rosenow F, Strzelczyk A. Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia. 2016. doi:10.1111/epi.13584.PubMed Kortland LM, Alfter A, Bähr O, Carl B, Dodel R, Freiman TM, Hubert K, Jahnke K, Knake S, von Podewils F, Reese JP, Runge U, Senft C, Steinmetz H, Rosenow F, Strzelczyk A. Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia. 2016. doi:10.​1111/​epi.​13584.PubMed
30.
go back to reference Sutter R, Marsch S, Fuhr P, Kaplan PW, Rüegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82:656–64.CrossRefPubMedPubMedCentral Sutter R, Marsch S, Fuhr P, Kaplan PW, Rüegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82:656–64.CrossRefPubMedPubMedCentral
Metadata
Title
Topiramate in the Treatment of Generalized Convulsive Status Epilepticus in Adults: A Systematic Review with Individual Patient Data Analysis
Authors
Francesco Brigo
Nicola Luigi Bragazzi
Stanley C. Igwe
Raffaele Nardone
Eugen Trinka
Publication date
01-01-2017
Publisher
Springer International Publishing
Published in
Drugs / Issue 1/2017
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0672-2

Other articles of this Issue 1/2017

Drugs 1/2017 Go to the issue